花与蛇之地狱篇

Our initiative focuses on designing and developing innovative tools and techniques to identify novel therapeutic targets, delivery mechanisms, and bioactive molecules with high potential for industry uptake and clinical translation. It is built on collective expertise in drug discovery research from across the University, underpinned by state-of-the-art infrastructure and input from industry and clinical advisory groups.

The Drug Discovery Initiative is supported by its team, members, and partners, underpinned by the University of Sydney’s Research Portfolio.

We are a point of contact for internal researchers looking to connect with complementary capability in the area of drug discovery research, or for external stakeholders looking to engage with our researchers.

Facilities钦州巨厚亨有限公司

Through Sydney Analytical, we have a suite of facilities to support and accelerate early-stage drug discovery including:

robotic and automated platforms for many routine processes in the drug discovery pipeline
state-of-the-art vibrational, NMR, EPR, X-ray diffraction and scattering spectrometers
protein production and purification facilities for bacterial, insect and mammalian expression systems
a fragment-based drug design platform, including Biacore and other in vitro assays
expertise and assistance in synchrotron and neutron characterisation and imaging techniques.

德阳长晶泰设备有限公司

Cancer 常德鑫凯美贸易有限公司

While therapies and prognoses for most cancers have improved drastically over the last two decades, there is still huge potential for further improvement through the development of targeted interventions and treatments, and a better understanding of the genetic and molecular mechanisms of cancers. We are working to develop bioactive molecules that enhance the understanding, prevention, and treatment of cancers.

Infectious diseases 洛阳国东鼎机械有限公司

With incidences of drug resistance increasing across many infectious diseases, there is a pressing need to develop new and more effective treatments. Our researchers are working to overcome disease resistance by discovering new targets and lead compounds to tackle diseases such as tuberculosis, malaria and fungal infections.

Inflammation 平顶山干瑞同贸易有限公司

Regulating the body’s inflammatory responses for treating pain and inflammation have applications in a growing list of disorders. Our research focuses on the identification and validation of novel targets implicated in pain, inflammation and autoimmunity, with potential applications in the understanding and treatment of cancers, central nervous system, metabolic and cardiovascular disorders.

Neurodegenerative and central nervous system disorders 雅安洪禄发服务有限公司

Neurodegenerative and central nervous system disorders such as dementia and systemic pain, are becoming increasingly prevalent with increasing life-spans. We are working to identify targets and develop lead compounds that selectively modulate the central nervous system.

Metabolic and cardiovascular diseases 汉中捷成汇设备有限公司

Diseases relating to metabolic and cardiovascular disorder, such as diabetes and obesity, represent a rapidly growing health problem in Australia and globally. Our researchers are pursuing therapeutic leads to target such diseases.

济宁干大盈设备有限公司

This 2-day conference features a range of speakers, with the first day focusing on cancer, infectious diseases, and Neuro-drug, and the second day focusing on dysfunctional proteostasis, protein aggregation diseases and proteinopathies, especially those related to neurodegeneration.

View the program of talks for the conference.

9-10 December 2019, Camperdown campus. Register now

邢台中安和贸易有限公司

丹江口宝升亨服务有限公司

Professor Michael Kassiou
Phone: +61 2 9351 2745
Email: michael.kassiou@sydney.edu.au

洮南大旺本有限公司

Julia Ning
Phone: +61 2 9114 4246
Email: julia.ning@sydney.edu.au

承德富旺万有限公司

Professor Mary Collins - Brain and Mind Centre
Associate Professor Greg Neely - Charles Perkins Centre
Associate Professor Wojtek Chrzanowski - Sydney Nano Institute
Professor James Triccas - Marie Bashir Institute
Dr Kristina Cook - Cancer Research Network
Professor Philip Robinson - Children’s Medical Research Institute
Professor Peter Lay - Sydney Analytical
Professor Paul Young - Commercialisation in Faculty of Medicine and Health, and Woolcock Institute of Medical Research
Professor Joel Mackay - Sydney Nano Institute